drugset / Trial / NCT04880564
A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies
Phase 1/2
Terminated
7 enrolled
Curon Biopharmaceutical (Australia) Co Pty Ltd
Novotech (Australia) Pty Limited · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study is designed to investigate the safety, tolerability and preliminary efficacy in combination with CN1 and CN401 in adult patients with relapsed/refractory lymphoid malignancies.
Timeline
- Start
- 2021-07-28
- Primary completion
- 2022-08-29
- Completion
- 2022-09-30
Outcome
Outcome not reported
Stopped: “Sponsor decided that there was no benefit in the drug treatment and due to company change in landscape in the new year.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CN1 | Unknown | 0.5 mg/kg | Intravenous |
| Subject | CN1 | Unknown | 1 mg/kg | Intravenous |
| Subject | CN1 | Unknown | 3 mg/kg | Intravenous |
| Subject | CN1 | Unknown | 10 mg/kg | Intravenous |
| Subject | CN401 | Unknown | 400 mg | Oral |
| Subject | CN401 | Unknown | 600 mg | Oral |
| Subject | CN401 | Unknown | 800 mg | Oral |